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Abstract 
 
 
 
A mathematical model is presented for predicting magnetic targeting of multifunctional 
carrier particles that are designed to deliver therapeutic agents to malignant tissue in vivo. 
These particles consist of a nonmagnetic core material that contains embedded magnetic 
nanoparticles and therapeutic agents such as photodynamic sensitizers. For in vivo 
therapy, the particles are injected into the vascular system upstream from malignant 
tissue, and captured at the tumor using an applied magnetic field. The applied field 
couples to the magnetic nanoparticles inside the carrier particle and produces a force that 
attracts the particle to the tumor. In noninvasive therapy the applied field is produced by a 
permanent magnet positioned outside the body. In this paper a mathematical model is 
developed for predicting noninvasive magnetic targeting of therapeutic carrier particles in 
the microvasculature. The model takes into account the dominant magnetic and fluidic 
forces on the particles and leads to an analytical expression for predicting their trajectory. 
An analytical expression is also derived for predicting the volume fraction of embedded 
magnetic nanoparticles required to ensure capture of the carrier particle at the tumor. The 
model enables rapid parametric analysis of magnetic targeting as a function of key 
variables including the size of the carrier particle, the properties and volume fraction of  
the embedded magnetic nanoparticles, the properties of the magnet, the microvessel, the 
hematocrit of the blood and its flow rate. 
 
 
 
Keywords: magnetic drug targeting, magnetic drug delivery, multifunctional 
nanoparticles, magnetic particle capture, nanoparticle transport in microvasculature, 
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1. Introduction 
 
Magnetic targeting of malignant tissue using multifunctional carrier particles has the 
potential to provide more effective anticancer treatment by enabling a variety of localized 
treatment and diagnostic modalities, while at the same time reducing undesired side 
effects. The interest in this therapy is growing due to recent progress in the development 
of carrier particles that are designed to target a specific tissue, and effect local chemo-, 
radio- and genetherapy at a tumor site [1-4]. In this paper we study in vivo magnetic 
targeting of carrier particles that consist of a nonmagnetic core material, such as 
polyarcylamide (PAA), with embedded magnetic nanoparticles and therapeutic agents 
such as photodynamic sensitizers (Fig. 1). Polyethylene glycol (PEG) and biotargeting 
agents can be coated onto the surface of the carrier particle to control plasma residence 
time and to promote binding to target tissue, respectively [5]. The magnetic nanoparticles 
embedded in the carrier particle enable multiple distinct therapeutic functions including 
magnetic targeting, RF hyperthermia and MRI contrast enhancement. Multifunctional 
carrier particles containing magnetic nanoparticles and a photosensitizer have proven to 
be effective in the treatment of brain tumors in mice by externally delivering reactive 
oxygen species (ROS) to cancer cells while simultaneously enhancing magnetic 
resonance imaging (MRI) contrast providing real-time tumor kill measurement [5].  
In this paper we study the magnetic targeting of therapeutic carrier particles in the 
microvasculature. We consider noninvasive therapy in which the particles are injected 
into the vascular system upstream from malignant tissue and captured at the tumor using 
an applied magnetic field provided by a cylindrical magnet positioned outside the body. 
We develop a mathematical model for predicting the transport and capture of the carrier 
particles taking into account the dominant magnetic and fluidic forces. The magnet is 
assumed to be of infinite extent, and oriented with its axis perpendicular to the blood flow 
(Fig. 1). It produces a magnetic field that couples to the magnetic nanoparticles inside the 
carrier particle, thereby producing a force that attracts the carrier particle to the tumor. 
The fluidic force is predicted using Stokes’ law for the drag on a sphere in a laminar flow 
field. The blood vessel is assumed to be cylindrical with laminar blood flow parallel to its 
axis. We use an empirically-based formula for the effective viscosity of blood in the 
microvasculature.    
We solve the equations governing the motion of the carrier particle, and obtain an 
analytical expression for predicting its trajectory in a microvessel. This expression can be 
used to predict viability of magnetic targeting as a function of the size of the carrier 
particle, the volume fraction of embedded magnetic nanoparticles, the properties of the 
magnet, the diameter of the microvessel, the hematocrit of the blood, and the flow rate. 
Our analysis demonstrates the viability of using noninvasive magnetic targeting for 
particle delivery to tumors that are within a few centimeters of the field source.  We also 
derive a formula for predicting the volume fraction of magnetic particles required to 
ensure capture of the carrier particle at the tumor. We show that larger carrier particles 
require smaller volume fractions.   
Lastly, while other models exist for predicting magnetic targeting of nanoparticles 
in vivo, many of these utilize numerical methods to solve for particle transport [6-9]. 
Thus, these models do not provide explicit functional relations for particle capture, and 
only a few account for the rheology of blood in the microvasculature [10-12]. The 
analytical model presented here is ideal for parametric analysis of magnetic targeting in 
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vivo, and should be useful for the development of novel magnetic targeting methods and 
apparatus.  
 
2. Mathematical Model 
 
Magnetic transport of a carrier particle in the vascular system is governed by several 
factors including  (a) the magnetic force, (b) viscous drag, (c) particle/blood-cell 
interactions, (d) inertia, (e) buoyancy,  (f) gravity, (g) thermal kinetics (Brownian motion), 
(h) particle/fluid interactions (perturbations to the flow field), and (i) interparticle effects 
such as magnetic dipole interactions. A rigorous analysis of these effects is beyond the 
scope of this work. Here, we take into account the dominant magnetic and viscous forces, 
and particle/blood-cell interactions using an effective viscosity. We predict particle 
transport by balancing the magnetic and fluidic forces, mF  and fF ,   
          m f 0+ =F F .  (1) 
In order to predict the magnetic force we need a model for the magnetic behavior of the 
carrier particle. To this end, we simplify the analysis and assume that there are mpN  
identical noninteracting magnetic nanoparticles embedded in the carrier particle. Each 
magnetic particle has a radius mpR  and a volume 
3
mp
4V
3 mp
Rπ= . We predict the force on a 
magnetic particle using an effective dipole moment approach in which the particle is 
replaced by an “equivalent” point dipole, which is located at its center [11]. The force 
depends on the magnetic field at the location of the dipole. Although the magnetic 
particles are distributed throughout the carrier particle, we compute the force on each 
particle using the field at the center of the carrier particle. Accordingly, the total magnetic 
force on the carrier particle is the sum of the forces on the embedded magnetic particles 
and is given by  
                ( ) ( )mpm 0 mp mp a amp
3
N V
3
χµ χ= ∇+F H Hi ,         (2) 
where aH  is the applied magnetic field intensity at the center of the carrier particle, 
mp
0
1mp
µχ µ= −  and mpµ are the susceptibility and permeability of the magnetic particles, 
and 70 4 10  H/mπ −µ = × is the permeability of air.  In arriving at Eq. (2), we have assumed 
that blood is essentially nonmagnetic with a permeability 0µ .  
The fluidic force is predicted using Stokes’ approximation for the drag on a 
sphere in a laminar flow field [13]   
                                                              f cp cp f6 R ( )πη= −F v - v .                      (3) 
Here, cpR is the radius of the carrier particle and η  and fv are the viscosity and the 
velocity of blood, respectively.   
2.1 Magnetic Force 
 
The first step in predicting the magnetic force is to determine the magnetic field of the 
magnet. The field components for an infinite cylindrical magnet that is magnetized 
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perpendicular to its axis are known and can be represented inside the blood vessel as [11, 
14], 
 
 
( )
( )
2 22
s
22 2
( )M
     H ( , )
2 ( )
mag
x
x d zR
x z
x d z
+ −=
+ +
, (4) 
and  
 ( )( )( )
2
s
22 2
M 2
( , )
2
mag
z
R x d z
H x z
x d z
+=
+ +
. (5) 
These are substituted into Eq. (2) to determine the magnetic force components, 
 ( )mp0 mp mp mp
3 ( , ) ( , )F ( , ) N V ( , ) ( , )
3
x x
mx x z
H x z H x zx z H x z H x z
x z
χµ χ
∂ ∂ = + ∂ ∂+   , (6) 
and   
          
 ( )mp0 mp mp mp
3 ( , ) ( , )F ( , ) N V ( , ) ( , )
3
z z
mz x z
H x z H x zx z H x z H x z
x z
χµ χ
∂ ∂ = + ∂ ∂+   . (7) 
Upon evaluation of Eqs. (6) and (7), followed by simplification, we obtain 
 
 
2 4
0 mp mp mp
2 2 3
mp
3 N V M ( )F
3 2(( ) )
s mag
mx
R x d
x d z
µ χ
χ
+= − + + + , (8) 
and 
 
2 4
0 mp mp mp
2 2 3
mp
3 N V M
F
3 2(( ) )
s mag
mz
R z
x d z
µ χ
χ= − + + + . (9) 
Equations (8) and (9) can be simplified further. Specifically, in noninvasive magnetic 
targeting the distance from the magnet to the blood vessel is much larger than the 
diameter of the blood vessel itself, and therefore / 1x d << . Also, the magnetic 
nanoparticles used in bioapplications are usually made from biocompatible materials such 
as magnetite (Fe3O4)  for which mp 1χ >> . Based on these assumptions, the magnetic force 
components reduce to  
 ( )
2 4
0 mp mp
32 2
3 N V M
F
2
s mag
mx
R
d z
µ= −
+
, (10) 
and 
 ( )
2 4
0 mp mp 32 2
F 3 N V M
2
mz s mag
zR
d z
µ= −
+
. (11) 
Since the magnetic force is confined to the x-z plane, it suffices to consider motion in this 
plane only, thereby reducing the analysis to two dimensions.   
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2.2 Fluidic Force 
 
To evaluate the fluidic force we need an expression for the fluid velocity fv  in the blood 
vessel. We assume that the vessel is cylindrical and that the blood flow is fully developed 
laminar flow parallel to the axis. Based on these assumptions, the blood velocity is 
 
           
2
f f
bv
v ( ) 2 v 1 xx
R
   = −    
      (12) 
 
where fv  is the average blood velocity and bvR is the radius of the blood vessel. The 
fluidic force components are determined by substituting Eq. (12) into Eq.  (3). We 
consider motion in the x-z plane and obtain, 
  
 fx cp cp,x6 R v ,πη= −F  (13) 
 
2
fz cp cp,z f
bv
6 ηR v 2 v 1 x
R
π      = − − −      
F . (14) 
 
An expression for the blood viscosity η  is needed to evaluate these components. We use 
the following experimentally determined analytical formula for blood viscosity in the 
microvasculature [15] 
 ( ) ( )( )
2 2
0.45
1 1
1 1
1.1 1.11 0.45 1
C
D
plasma C
H D D
D D
η η η − −    = + −    − −   − −  
, (15) 
where 3 21.2 10  N s/mplasmaη −= × ⋅  is the viscosity of blood plasma (without the cells and 
platelets), D is the diameter of the blood vessel in microns, HD is the hematocrit 
(nominally 0.45), and  
 
0.6450.085 0.06
0.45 6 3.2 2.44
D De eη − −= ⋅ + − , (16) 
and 
 ( )0.075 11 12 11 121 10.8 11 10 1 10DC e D D− − − = + ⋅ − + + ⋅ + ⋅  . (17) 
Equations (13) and (14) are used in the equations of motion below. 
2.3 Equations of Motion 
 
The equations of motion for a carrier particle traveling through a microvessel can be 
written in component form by substituting Eqs. (8), (9),  (13) and (14) into Eq.  (1). We 
solve for the velocity components in the x-z plane and obtain, 
 
 
2 4
0 mp mp s mag
cp,x 2 2 3
cp
3 N V M R 1v =
6 R 2(d z )
µ
πη + , (18) 
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and 
 ( )
22 4
0 mp mp
cp,z f32 2
cp bv
3 N V M
v 2 v 1
6 R 2
s magR z x
Rd z
µ
πη
   = + −   +   
. (19) 
Equations. (18) and (19) are coupled and can be solved  numerically to predict the 
particle trajectory (x(t),z(t)). However, it is possible to uncouple these equations and 
obtain an analytical solution. Specifically, for practical noninvasive targeting systems,  
 
 
2 4
0 mp mp
cp
3 N V M
1
6 R
s magRµ
πη  , (20) 
and therefore the fluidic force in Eq. (19) is dominant. We simplify the analysis by 
assuming that the average axial velocity of the carrier particle cp,zv  equals the average 
blood flow velocity,    
 cp,z fv v .=  (21) 
 
Based on this assumption, the axial position of the particle is given by  
 0 fvz z t= + . (22) 
Thus, the axial motion is uncoupled from the radial motion.  
 
We substitute Eq. (22) into Eq. (18) and obtain 
 
 
 
2 2 4
0 vf cp s mag
32 2
0 f
4 R M Rdx(t) d=
dt 6 (d (z v t)
µ β
η  + + 
 (23) 
where cp,x
dx(t) v
dt
= , and 
                mp mp vf cp vfN V V                     (0 1)= β < β ≤ . (24) 
In Eq. (24) we have represented the total volume occupied by the nanoparticles mp mpN V  
in terms of a volume fraction vf cpVβ of the carrier particle itself. We integrate Eq. (23) to 
obtain analytical expression for the position x(t) of the particle, 
  
 
0 o
2 2 4x(t) t
0 vf cp s mag
32 2
x t 0 f
4 R d M R ddx =
6 (d (z v )
µ β τ
η  + + τ 
∫ ∫ . (25) 
This reduces to  
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( )
( )
2 2 4
0 vf cp 0 f 0
0 2 22 2 2 2 2 2
f 0 f 0
0 f 0
2 2 2 2 2 2 2
0 f 0
1 10 f 0
3 3
4 R M v( )
6 v 4 ( v ) 4
v3
4 2 ( v ) 2
v1 1tan tan .
2 2
s magd R z t zx t x
d d z t d d z
z t z
d d d z t d d z
z t z
d d d d
µ β
η
− −
 += + −  + + +  
 ++ − + + +  
+    + −       
 (26) 
 
Equations (22) and (26) can be used to predict the trajectory of the particle (x(t), z(t)) 
given its initial position 0 0( , ).x z We assume that the particle is captured if its trajectory 
reaches the inner wall of the blood vessel, which occurs when bv( )x t R= − .  
We can use Eq. (26) to predict the volume fraction of magnetic particles required to 
ensure capture of a carrier particle.  To this end, we consider the motion of a carrier 
particle that starts out at the top of the microvessel (farthest vertical distance from the 
magnet), i.e. at 0 bvx R= . If this particle is to be captured above the center of the magnet 
(i.e., at 0z = ) then its terminal position is bv( )x t R=  at 0z = , i.e., when 0 f/ vt z= . We 
substitute these values into Eq. (26) and solve for vfβ ,     
 ( ) ( )
1
1bv f 0 0 0
vf,100 22 2 4 54 2 22 2 2
0 cp 00
3R v 3 3 tan
R M 884s mag
z z z
d R d dd d zd d z
ηβ µ
−
−
   = + +   +  + 
. (27) 
Now, any carrier particle that starts closer to the magnet, i.e., bv 0 bvR x R− < < , will be 
captured to the left of the magnet (i.e., 0z < ). Thus, vf,100β  represents the volume fraction 
of magnetic nanoparticles in a carrier particle that is required to ensure its capture before 
or above the center of the magnet (i.e., 0z ≤ ), and Eq. (27) gives explicit functional 
dependencies for this value. Notice that -2vf,100 cpRβ ∝ , and therefore larger carrier particles 
require a smaller volume fraction of magnetic particles to ensure capture. Also, 
vf,100 1/ dβ ∝ , which implies that the volume fraction of magnetic particles needed for  
therapy decreases for tumors that are closer to the surface of the body. Equations (22), 
(26), and (27) constitute an analytical mathematical model for predicting the magnetic 
targeting of multifunctional carrier particles in the vascular system. 
3. Results 
 
We use the model derived above to study the capture of carrier particles with 
embedded magnetite (Fe3O4) nanoparticles. We adopt a magnetization model for Fe3O4 
described by Takayasu et al., which is consistent with a magnetic susceptibility np 1χ >> , 
and hence consistent with our model [11], [16].  Specifically, 
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a sp
a
a a sp
3 H M / 3
(H )
M / H H M / 3
f
 <=  ≥ sp
. (28) 
For the field source, we use a rare-earth NdFeB magnet, 6 cm in diameter ( magR  = 3.0 
cm), with a magnetization 6M 1 10  A/ms = × (remanence B 1.256 Tr = ). The surface of 
the magnet is positioned 2.5 cm from the axis of the microvessel (d = 5.5 cm in Fig. 2). 
We choose a microvessel with a radius bvR = 50 µm, and an average flow velocity 
fv 10 mm/s=  To determine the effective viscosity, we assume 
20.0012 N s/mplasmaη = ⋅ and a hematocrit of 45%.  
First, we use Eq. (27) to determine vf,100β  for a range of carrier particle sizes: 
cpR = 200 -1000 nm. The initial axial position of each particle is 0 4 magz R= − , which is 
far enough upstream from the magnet so that the magnetic force is initially negligible. 
From this analysis we find that it is not possible to ensure 100% capture of all of the 
particles (Figure 3). Specifically, particles with cpR 375nm≤ require a volume fraction 
vf,100 1β > , which is impossible to achieve as the maximum possible volume fraction is 1, 
which occurs when the entire carrier particle is magnetic. Notice that larger carrier 
particles require smaller magnetic volume fractions for captrure, and the functional 
dependency is -2vf,100 cpRβ ∝ , which follows from Eq. (27) 
Next, to check the analysis above, we use Eqs. (22) and (26) to predict the 
trajectories of nine identical carrier particles with cpR = 500 nm, for a range of initial 
positions along the x-axis: 0x  = bv0.8R− , bv0.6R− , …, bv1.0R .  All other parameters are as 
above. We compute two sets of trajectories: the first set is computed using a magnetic 
particle volume fraction of 56%, which from Figure 3 should ensure the capture of all the 
carrier particles. The predicted trajectories are shown in Figure 4a. Notice that all of the 
particles are captured either before or at the center of the magnet, i.e. 0z ≤ , which is 
consistent with data in Figure 3. The second set of trajectories is computed using a 
magnetic particle volume fraction of 20%, which from Figure 3 should result in partial 
carrier particle capture. The predicted trajectories do confirm partial capture as shown in 
Figure 4b. Specifically, carrier particles that start at 0 0.6 bvx R≥  escape capture.   
Lastly, we use Eq. (27) to compute vf,100β  as a function of cpR for four different 
magnet to blood vessel distances d = 50 mm, 60 mm, 70 mm and 80 mm, which 
correspond to spacings of 20 mm, 30 mm, 40 mm and 50 mm, respectively, between the 
edge of the magnet and the center of the microvessel (Figure 5). As expected, the carrier 
particle size and volume fraction required for capture increase when the microvessel is 
farther from the magnet.  
In summary, the analysis demonstrates the viability of using noninvasive 
magnetic therapy for drug targeting to malignant tissue that is within a few centimeters 
from the surface of the body. Moreover, the theory developed herein can be used to 
determine the optimum magnet parameters and particle size for treating a tumor, given its 
size and location within the body. Thus, this work should useful in the development of 
new drug targeting apparatus and treatments.  
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4. Conclusion 
 
We have developed a mathematical model for studying magnetic targeting of therapeutic 
carrier particles in the microvasculature. The model applies to noninvasive therapy and 
takes into account the dominant magnetic and fluidic forces that govern the motion of a 
carrier particle. A key result of this work is an analytical formula for predicting the 
volume fraction of magnetic nanoparticles embedded in the carrier particle that is 
required to ensure its capture at the tumor. We have used the model to study magnetic 
targeting, and our results indicate that this can be achieved using submicron carrier 
particles when the tumor is within a few centimeters of the surface of the body.  
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FIGURE CAPTIONS 
 
FIG. 1. Noninvasive magnetic targeting of multifunctional carrier particles.  
FIG. 2. Geometry and reference frame for analysis. 
FIG. 3. Volume fraction required for 100% capture vs. carrier particle radius.  
FIG. 4. Trajectories of carrier particles (Rcp = 500 µm) in a microvessel: (a) 100% 
capture (Fe3O4 volume fraction = 56%), and  (b) partial capture (Fe3O4 volume fraction = 
20%). 
FIG. 5. Analysis of vf,100β  (volume fraction required for capture) as a function of the 
radius of the carrier particle and the spacing between the magnet and the microvessel.  
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